4//SEC Filing
BIOTECHNOLOGY VALUE FUND L P 4
Accession 0000921895-25-002742
CIK 0001633932other
Filed
Oct 13, 8:00 PM ET
Accepted
Oct 14, 5:33 PM ET
Size
27.8 KB
Accession
0000921895-25-002742
Insider Transaction Report
Form 4
ESSA Pharma Inc.EPIX
BVF GP HOLDINGS LLC
10% Owner
Transactions
- Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total - Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total - Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total
Transactions
- Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total - Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total - Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total
BVF II GP LLC
Other
Transactions
- Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total - Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total - Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total
Transactions
- Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total - Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total - Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total
BVF PARTNERS L P/IL
10% Owner
Transactions
- Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total - Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total - Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total
BVF Partners OS Ltd.
Other
Transactions
- Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total - Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total - Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total
BVF I GP LLC
10% Owner
Transactions
- Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total - Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total - Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total
BIOTECHNOLOGY VALUE FUND L P
10% Owner
Transactions
- Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total - Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total - Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total
LAMPERT MARK N
10% Owner
Transactions
- Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total - Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total - Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total
BVF INC/IL
10% Owner
Transactions
- Disposition from Tender
Common Stock
2025-10-09−4,726,743→ 0 total - Disposition from Tender
Common Stock
2025-10-09−6,194,145→ 0 total - Disposition from Tender
Common Stock
2025-10-09−560,797→ 0 total
Footnotes (6)
- [F1]This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- [F2]This Form 4 reports securities disposed of pursuant to an arrangement under Section 288 of the Business Corporations Act (British Columbia) involving the Issuer, XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), a wholly-owned subsidiary of Parent, and XOMA Royalty Corporation pursuant to a business combination agreement dated July 13, 2025, and the plan of arrangement, pursuant to which, among other things, the Purchaser acquired all of the outstanding shares of common stock of the Issuer, effective October 9, 2025 (the "Merger").
- [F3]Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- [F4]Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- [F5]Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- [F6]The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $0.124231 in cash per share of common stock (excluding the approximately $1.69 of cash per share of common stock previously distributed to the Issuer's shareholders) and one contingent value right per share of common stock for potential cash payments of up to approximately $0.14 per share of common stock.
Documents
Issuer
ESSA Pharma Inc.
CIK 0001633932
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0000918923
Filing Metadata
- Form type
- 4
- Filed
- Oct 13, 8:00 PM ET
- Accepted
- Oct 14, 5:33 PM ET
- Size
- 27.8 KB